DAX23.591 -1,2%Est505.641 -0,9%MSCI World4.343 -0,1%Top 10 Crypto12,16 -3,5%Nas22.708 -0,8%Bitcoin79.200 -2,6%Euro1,1588 -0,3%Öl64,08 -0,3%Gold4.040 -1,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 DroneShield A2DMAA Siemens Energy ENER6Y Alphabet A (ex Google) A14Y6F Siemens 723610 Deutsche Telekom 555750 Netflix 552484 RENK RENK73 SAP 716460 Tesla A1CX3T Amazon 906866 Novo Nordisk A3EU6F Lufthansa 823212 Allianz 840400
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX schließt tiefrot -- US-Börsen schwach -- Buffett schlägt bei Alphabet-Aktie zu -- Netflix mit Mega-Aktiensplit -- NVIDIA, Palantir, Rüstungsaktien, Amazon, Geely, DroneShield, Plug Power im Fokus
Top News
Frühstart in die Zukunft - das Kinderdepot von finanzen.net ZERO Frühstart in die Zukunft - das Kinderdepot von finanzen.net ZERO
Netflix-Aktie ab heute deutlich günstiger: Was der Mega-Aktiensplit für Aktionäre bedeutet Netflix-Aktie ab heute deutlich günstiger: Was der Mega-Aktiensplit für Aktionäre bedeutet
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Kyverna Therapeutics Aktie

Kaufen
Verkaufen
7,16 USD +0,28 USD +3,99 %
BTT
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.259,40 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA402W6

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS5019761049

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolKYTX

Kyverna Therapeutics Aktien News

DatumMeistgelesen
PR NewswireKyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise
PR NewswireKyverna Therapeutics to Present at the Jefferies Global Healthcare Conference
PR NewswireKyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
PR NewswireKyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
PR NewswireKyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference
ZacksWhat Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock
PR NewswireKYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Kyverna Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - KYTX
PR NewswireLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. Lawsuit - KYTX
PR NewswireKyverna Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTX
PR NewswireONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics
PR NewswireKyverna Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights - KYTX
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Kyverna Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - KYTX
PR NewswireKYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit
PR NewswireKYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Fraud Lawsuit
PR NewswireKyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Kyverna Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - KYTX
PR NewswireKyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Kyverna Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - KYTX
PR NewswireKyverna Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX
PR NewswireKyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference
PR NewswireKYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm
PR NewswireFebruary 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against KYTX
PR NewswireKyverna Therapeutics, Inc. Investors with Large Losses Are Encouraged to Contact Shareholder Rights Law Firm Robbins LLP for Information About the KYTX Class Action Lawsuit
PR NewswireDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics
PR NewswireKYTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
PR NewswireClass Action Filed Against Kyverna Therapeutics, Inc. (KYTX) Seeking Recovery for Investors - Contact Levi & Korsinsky
PR NewswireKyverna Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights - KYTX
PR NewswireClass Action Filed Against Kyverna Therapeutics, Inc. (KYTX) - February 7, 2025 Deadline to Join - Contact Levi & Korsinsky
PR NewswireKyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth
PR NewswireKYTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
PR NewswireKyverna Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX
PR NewswireKyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024
PR NewswireKyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
PR NewswireKyverna Therapeutics Appoints Mert Aktar to its Board of Directors
PR NewswireKyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024
PR NewswireKyverna Therapeutics Announces Leadership Update
PR NewswireKyverna Therapeutics to Participate in Upcoming September Investor Conferences
PR NewswireKyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
PR NewswireKyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis

Kyverna Therapeutics News

Kyverna Therapeutics News: auf dieser Seite finden Sie alle Kyverna Therapeutics News und Nachrichten zur Kyverna Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Kyverna Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Kyverna Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.